Clinical Trial Details
| Trial ID: | L3618 |
| Source ID: | NCT00034255 |
| Associated Drug: | Ingap Peptide |
| Title: | Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: INGAP Peptide |
| Outcome Measures: | |
| Sponsor/Collaborators: | Sponsor: GMP Endotherapeutics |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1|PHASE2 |
| Enrollment: | 62 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT |
| Start Date: | 2001-12 |
| Completion Date: | |
| Results First Posted: | |
| Last Update Posted: | 2005-06-24 |
| Locations: | VASDHS Medical Center, San Diego, California, 92161, United States|MedStar Research Institute - Clinical Research Center, Washington, District of Columbia, 20003, United States|UNC Diabetes, Endocrinology, Metabolism Clinic, Durham, North Carolina, 27713, United States|Texas Diabetes Institute, San Antonio, Texas, 78284, United States |
| URL: | https://clinicaltrials.gov/show/NCT00034255 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|